(NASDAQ: COCP) Cocrystal Pharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 23.12%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 68.66%.
Cocrystal Pharma's earnings in 2026 is -$8,831,000.On average, 4 Wall Street analysts forecast COCP's earnings for 2026 to be -$9,421,188, with the lowest COCP earnings forecast at -$9,862,332, and the highest COCP earnings forecast at -$8,829,779. On average, 3 Wall Street analysts forecast COCP's earnings for 2027 to be -$8,999,343, with the lowest COCP earnings forecast at -$8,646,428, and the highest COCP earnings forecast at -$9,264,030.
In 2028, COCP is forecast to generate -$9,843,032 in earnings, with the lowest earnings forecast at -$9,457,031 and the highest earnings forecast at -$10,132,533.